ProQR Therapeutics (PRQR) Times Interest Earned (2014 - 2026)
ProQR Therapeutics (PRQR) posted Times Interest Earned of -$290.4 for Q1 2026, down 5323.73% sequentially from -$5.35 in Q4 2025, and down 463.84% YoY from $79.82 in Q1 2025.
ProQR Therapeutics (PRQR) Times Interest Earned (2014 - 2026) Analysis & Trends
ProQR Therapeutics has reported Times Interest Earned for 12 years, with the latest figure at -$290.4 in Q1 2026.
- Quarterly Times Interest Earned fell 463.84% year-over-year to -$290.4 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$28.0 (down 55.35% YoY) and the FY2025 annual result came in at -$33.76, down 20.09% from the prior year.
- Times Interest Earned eased to -$290.4 in Q1 2026 per PRQR's latest filing, from -$5.35 in the prior quarter.
- Over five years, Times Interest Earned peaked at $74.73 in Q3 2025 and troughed at -$290.4 in Q1 2026.
- A 4-year average of -$33.48 and a median of -$5.35 in 2025 frame the typical range for Times Interest Earned.
- The widest YoY moves for Times Interest Earned: up 87.76% in 2025, down 1143.22% in 2025.
- Over 4 years, Times Interest Earned stood at -$1.71 in 2022, then sank by 252.9% to -$6.02 in 2024, then climbed by 11.04% to -$5.35 in 2025, then sank by 5323.73% to -$290.4 in 2026.
- According to Business Quant data, Times Interest Earned over the past three periods registered -$290.4, -$5.35, and $74.73 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | ProQR Therapeutics | 206.80 Mn | 111.86 Mn | - | -290.40 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -290.40 |
| Dec 31, 2025 | -5.35 |
| Sep 30, 2025 | 74.73 |
| Jun 30, 2025 | -235.56 |
| Mar 31, 2025 | -51.50 |
| Dec 31, 2024 | -6.02 |
| Sep 30, 2024 | 39.80 |
| Jun 30, 2024 | -18.95 |
| Mar 31, 2024 | 42.72 |
| Dec 31, 2022 | -1.71 |
| Sep 30, 2022 | 18.14 |
| Jun 30, 2022 | 12.80 |
| Mar 31, 2022 | -13.98 |
| Dec 31, 2021 | 32.39 |
| Sep 30, 2021 | 25.95 |
| Jun 30, 2021 | 22.96 |
| Mar 31, 2021 | 20.94 |
| Dec 31, 2020 | 23.06 |
| Sep 30, 2020 | 19.09 |
| Jun 30, 2020 | 98.79 |